
    
      This is a multicenter, randomized, open label, phase II study assessing the efficacy and
      safety of penpulimab plus chemotherapy or penpulimab plus anlotinib or penpulimab plus
      chemotherapy and anlotinib as neoadjuvant/adjuvant treatment in patients with resectable
      locally advanced non-small cell lung cancer. Eligible patients will be randomized to receive
      either penpulimab (200mg, iv, Q3W) plus chemotherapy (platinum based chemotherapy) or
      penpulimab (200mg, iv, Q3W) plus anlotinib (12mg, po, day 1-14, Q3W) or penpulimab (200mg,
      iv, Q3W) plus chemotherapy (platinum based chemotherapy) and anlotinib (12mg, po, day 1-14,
      Q3W) in a 1:1:1 ratio.
    
  